Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06610825 · ClinicalTrials.gov registry record · Phase 2
Castrate Resistant Prostate Cancer Enhertu Therapy
A Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic, sponsored by Washington D.C. Veterans Affairs Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06610825 is a Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic that is actively recruiting participants, run by Washington D.C. Veterans Affairs Medical Center. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06610825, a Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic, is actively recruiting participants, sponsored by Washington D.C. Veterans Affairs Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Conditions Studied
Interventions
- DRUG Enhertu
Study Locations (1)
District of Columbia
- Washington DC VAMC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06610825
The ClinicalTrials.gov registry entry for NCT06610825 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Washington D.C. Veterans Affairs Medical Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Enhertu is the first listed.
NCT06610825 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06610825 about?
NCT06610825 is a clinical study titled "Castrate Resistant Prostate Cancer Enhertu Therapy". Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
What is the current status of trial NCT06610825?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03-05. Estimated completion is 2028-10.
What conditions does trial NCT06610825 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Metastatic, CRPC.
What interventions are being tested in trial NCT06610825?
The interventions under investigation include: Enhertu (DRUG).
Who is sponsoring clinical trial NCT06610825?
This trial is sponsored by Washington D.C. Veterans Affairs Medical Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06610825 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Prostate Cancer
All registered trials for this condition
Prostate Cancer Metastatic
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.